MOLECULAR PARTNERS
Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics.
MOLECULAR PARTNERS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2004-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.molecularpartners.com
Total Employee:
51+
Status:
Active
Contact:
+41 44 755 77 00
Email Addresses:
[email protected]
Total Funding:
188.82 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
HUTCHMED (China) Limited
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company.
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company.
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Aurealis Pharma
Aurealis Pharma is a biopharmaceutical company.
Basilea Pharmaceutica
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company.
BioInvent
BioInvent is a research-based pharmaceutical company.
Biomics Biopharma
Biomics Biopharma is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Diatech Pharmacogenetics
Diatech Pharmacogenetics is an Italian Precision Medicine company.
Exvastat
Exvastat is an innovative, preclinical-stage pharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Halia Therapeutics
Halia is a preclinical-stage biopharmaceutical company.
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
Humanetics Corporation
clinical stage pharmaceutical company.
Kringle Pharma
Kringle Pharma is a biopharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Lipid Pharmaceuticals
Lipid Pharmaceuticals is a clinical-stage, privately held, pharmaceutical development company.
MetrioPharm
MetrioPharm is a clinical stage pharmaceutical development company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Novaremed AG
Novaremed AG is a clinical-stage Swiss biopharmaceutical company.
NuCana
NuCana is a clinical-stage biopharmaceutical company
Proveca
Proveca is a UK based pharmaceutical company.
SeQuent Scientific
SeQuent Scientific Limited is an India-based integrated pharmaceutical company.
UroGen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies.
Zelluna Immunotherapy
Zelluna Immunotherapy is a privately owned Norwegian biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Novartis
Novartis investment in Post-IPO Equity - Molecular Partners
Federated Kaufmann Fund
Federated Kaufmann Fund investment in Post-IPO Equity - Molecular Partners
BVF Partners
BVF Partners investment in Post-IPO Equity - Molecular Partners
Camber Capital Corp
Camber Capital Corp investment in Post-IPO Equity - Molecular Partners
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Molecular Partners
Endeavour Vision
Endeavour Vision investment in Series B - Molecular Partners
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Series B - Molecular Partners
Index Ventures
Index Ventures investment in Series B - Molecular Partners
BB Biotech Ventures
BB Biotech Ventures investment in Series B - Molecular Partners
Essex Woodlands Healthcare Partners
Essex Woodlands Healthcare Partners investment in Series B - Molecular Partners
Official Site Inspections
http://www.molecularpartners.com Semrush global rank: 768.67 K Semrush visits lastest month: 51.76 K
- Host name: apollo-18524850-129.titandc.io
- IP address: 185.248.50.129
- Location: Spain
- Latitude: 40.4172
- Longitude: -3.684
- Timezone: Europe/Madrid
More informations about "Molecular Partners"
PIONEERING DARPin THERAPEUTICS - Molecular Partners
Nov 7, 2024 · From radiopharmaceuticals to immune cell engagers, we are going beyond the limits of today’s leading treatments for cancer patients. We are deeply motivated to deliver …See details»
About Us - Molecular Partners
We are pioneers: inventors and developers of DARPin therapeutics, an entirely new class of custom-built drugs. As our name indicates, collaboration is in our DNA: within our team, with our partners, and with patients and providers.See details»
Molecular Partners - Wikipedia
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has tw…See details»
Partnering - Molecular Partners
Our partnerships are tailored to the DARPin therapeutic and MoA in question, the medical problem and indication, as well as MP’s and the partner’s needs and objectives. We strive for …See details»
Molecular Partners - Crunchbase Company Profile & Funding
Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing …See details»
Corporate Presentation - Molecular Partners
These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com.See details»
Molecular Partners - LinkedIn
Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical …See details»
Molecular Partners | LinkedIn
Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical …See details»
Molecular Partners AG - Swiss Biotech
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of a novel class of DARPin therapeutics, a novel class …See details»
Molecular Partners Reports H1 2024 Corporate Highlights and …
Jun 30, 2024 · Molecular Partners has leveraged the intrinsic properties of DARPins, such as small size, high affinity and specificity, to engineer Radio-DARPins as ideal vector candidates …See details»
Molecular Partners Reports Corporate Highlights From Q4 2021 …
Mar 15, 2022 · Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin therapeutics, …See details»
DARPin Science - Molecular Partners
We have pioneered DARPin (Designed Ankyrin Repeat Protein) therapeutics, a new class of custom-built drugs based on natural binding proteins that open new dimensions of multi …See details»
Molecular Partners - Craft
Oct 11, 2024 · Molecular Partners is a biopharmaceutical company that focuses on the discovery, development, and commercialization of biopharmaceutical products for the treatment of wet …See details»
Molecular Partners Announces Shareholders Approve All Board …
Apr 4, 2023 · The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS consolidated financial statements and the annual statements for the financial year 2022.See details»
Molecular Partners - Overview, News & Similar companies
Apr 29, 2024 · View Molecular Partners (www.molecularpartners.com) location in Zurich, Switzerland , revenue, industry and description. Find related and similar companies as well as …See details»
Careers - Molecular Partners
Molecular Partners offers an international working environment and the opportunity to collaborate with 160+ outstanding individuals from numerous disciplines who contribute to our shared …See details»
Molecular Partners Reports H1 2023 Corporate Highlights and …
Jun 30, 2023 · The results presentation, this press release, and the H1 2023 report will be made available on www.molecularpartners.com after 10:00pm (CET) on August 24, 2023. H1 2023 …See details»
General-purpose machine-learned potential for 16 elemental
3 days ago · Machine-learned potentials are accurate but often lack broad applicability. Here, authors develop a general-purpose neuroevolution potential for 16 metals and their alloys, …See details»
Pipeline - Molecular Partners
In January 2024, Molecular Partners entered into a co-development agreement with Orano Med, a pioneer in targeted alpha therapy, to develop novel RDTs that use Orano Med’s 212 Pb …See details»
Molecular Partners Receives Orphan Drug Designation for MP0250 …
Dec 27, 2019 · Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan …See details»